{"id":"W4221105120","doi":"10.1200/jco.21.02678","title":"Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; Stollery Children's Hospital; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Internal medicine; Regimen; Lymphoblastic lymphoma; Prednisone; Proteasome inhibitor; Clinical trial; Lymphoma; Oncology; Multiple myeloma; Dexamethasone; Surgery; Gastroenterology; Immunology; T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003045926,0.0008284343,0.001463852,0.0003870418,0.0003843142,0.0007889941,0.0008627122,0.0009193977,0.002048912],"category_scores_gemma":[0.00164715,0.0003007095,0.001051066,0.0005117225,0.000741889,0.000424171,0.0003515385,0.002365532,0.0003992188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001386389,"about_ca_system_score_gemma":0.003248141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001887015,"about_ca_topic_score_gemma":0.008908432,"domain_scores_codex":[0.998329,0.001126289,0.00006420199,0.0001558123,0.000157889,0.0001668404],"domain_scores_gemma":[0.9982809,0.0003044696,0.0005470653,0.00008037637,0.00007515487,0.0007120459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7294971,0.01850241,0.040814,0.001409592,0.002854311,0.0003442571,0.0002125324,0.003281062,0.0195214,0.001160031,0.01693619,0.165467],"study_design_scores_gemma":[0.7649202,0.1641758,0.04570131,0.0002677388,0.001676855,0.0008098479,0.00007350512,0.00201013,0.004045009,0.0005529974,0.01570342,0.00006324439],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804127,0.008139858,0.0004265892,0.001981089,0.0002637281,0.003050457,0.001680619,0.00007581396,0.003969015],"genre_scores_gemma":[0.9804074,0.004933891,0.003231543,0.002707141,0.0005080955,0.003830902,0.002296794,0.00003577912,0.002048433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003045926,"threshold_uncertainty_score":0.01610863,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1056531384057165,"score_gpt":0.4566537923573419,"score_spread":0.3510006539516254,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}